Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to Richard T. Kloos, M.D., Veracyte’s executive medical director.

“Dr. Klopper is an exceptional addition to Veracyte’s world-class medical team,” said Dr. Kloos. “He was an investigator on the study that demonstrated the clinical utility of our original Afirma genomic classifier for reducing unnecessary surgeries in thyroid nodule evaluation, so is extremely knowledgeable about the test and its clinical value. More broadly, his extensive clinical and research experience, particularly in thyroid nodule and thyroid cancer management, will help us achieve our vision of improving outcomes for patients all over the world at every step of their journey.”

Dr. Klopper most recently served as regional service chief of the Colorado Permanente Medical Group (CPMG) of Kaiser Permanente. Prior to his work at CPMG, Dr. Klopper was a full-time faculty member in the Division of Endocrinology at the University of Colorado School of Medicine, where he specialized in thyroid nodule and thyroid cancer evaluation and management. Dr. Klopper was the co-director of the Endocrine Society Introductory Hands-On Thyroid Ultrasound Workshop for five years and has served on the American Thyroid Association board of directors.

Dr. Klopper graduated from the Emory University School of Medicine. He completed his internship and residency in internal medicine at the University of Colorado Health Sciences Center (UCHSC). He subsequently completed both a postdoctoral research fellowship in the Endocrinology Division of UCHSC and an endocrinology fellowship.

“Over the course of my nearly 20 years providing care for patients with thyroid nodules and thyroid cancer, I’ve witnessed the growing, positive impact of genomic information and technologies,” said Dr. Klopper. “I am thrilled to join the truly impressive medical team at Veracyte, a company that is leading the way in this area to improve patient outcomes and the standard of care.”

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.